News
AGIO
37.90
+4.70%
1.70
Agios Pharmaceuticals (AGIO) Could Be 11% Undervalued Following Its Rare Disease Growth Narrative
Simply Wall St · 3d ago
Agios Pharmaceuticals (AGIO) Is Up 10.3% After New Mitapivat Phase 3 Data and Share Filing – Has The Bull Case Changed?
Simply Wall St · 5d ago
Weekly Report: what happened at AGIO last week (0615-0619)?
Weekly Report · 6d ago
Agios Pharma Shareholders Expand Equity Plan, Reelect Directors
TipRanks · 06/18 20:38
Agios Pharmaceuticals shareholders approve 2 million-share increase to 2023 stock incentive plan
PUBT · 06/18 20:14
Agios Targets Transfusion Burden in Sickle Cell Disease With New Phase 3 Bet on Mitapivat
TipRanks · 06/18 16:33
Agios Pharmaceuticals (AGIO) Stock Could Be 22% Undervalued After RISE UP Phase 3 Data
Simply Wall St · 06/17 16:28
Agios Maintained at Hold as Analyst Keeps $32 Price Target Amid Clinical Progress and Competitive Sickle Cell Risks
TipRanks · 06/15 13:45
Truist Financial Keeps Their Buy Rating on Agios Pharma (AGIO)
TipRanks · 06/15 12:18
Emily Bodnar Reiterates Buy on Agios, Citing Strong Mitapivat SCD Profile and Raising Price Target to $54
TipRanks · 06/15 10:36
Agios Pharmaceuticals (AGIO) Is Up 7.4% After Mitapivat RISE UP Data in Sickle Cell Disease - Has The Bull Case Changed?
Simply Wall St · 06/15 10:18
Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright
TipRanks · 06/15 10:06
AGIOS PHARMACEUTICALS, INC. <AGIO.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $54 FROM $50
Reuters · 06/15 10:01
Weekly Report: what happened at AGIO last week (0608-0612)?
Weekly Report · 06/15 09:16
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
Reuters · 06/15 07:49
Reported Saturday, Agios Presents RISE UP Phase 3 Data At EHA 2026 Showing Mitapivat Achieves 40.6% Hemoglobin Response Rate And 41.1% Reduction In Transfusion Burden Versus Placebo In Sickle Cell Disease
Benzinga · 06/15 07:16
Agios posts EHA 2026 investor event presentation on rare hematology pipeline
PUBT · 06/15 04:20
Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat
TipRanks · 06/14 20:35
Agios says Phase 3 RISE UP trial shows mitapivat boosts hemoglobin response in sickle cell disease patients
PUBT · 06/13 13:00
AGIOS SHOWCASES RISE UP PHASE 3 RESULTS AT EHA 2026 PLENARY SESSION REINFORCING STRONG ANTI-HEMOLYTIC PROFILE OF MITAPIVAT IN SICKLE CELL DISEASE
Reuters · 06/13 13:00
More
Webull provides a variety of real-time AGIO stock news. You can receive the latest news about Agios Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.